Molecular mechanisms of mild and moderate hemophilia A

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 3, 2003, Pages 456-463

  Jacquemin, M ^a   De Maeyer, M ^b   D'Oiron, R ^a   Lavend'Homme, R ^a   Peerlinck, K ^a   Saint Remy, J M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Factor IX; Factor VIII; Hemophilia A; von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9A; THROMBIN; VON WILLEBRAND FACTOR;

BIOSYNTHESIS; CHEMISTRY; GENETICS; HEMOPHILIA A; HUMAN; METABOLISM; MUTATION; REVIEW;

FACTOR IXA; FACTOR VIII; HEMOPHILIA A; HUMANS; MUTATION; THROMBIN; VON WILLEBRAND FACTOR;

EID: 0642280712     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00088.x     Document Type: Review

References (54)

1. Vehar GA, Keyt B, Eaton D, Rodriguez H, O'Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham EG, Lawn R, Capon D. Structure of human factor VIII. Nature 1984; 312: 337-42.
2. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the vonWillebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977; 60: 390-404.
3. Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EG, Kemball-Cook G. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 1997; 89: 2413-21.
4. Liu ML, Shen BW, Nakaya S, Pratt K, Fujikawa K, Davie E, Stoddard BL. Hemophilic factor VIII, C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. Blood 2000; 96: 979-87.
5. Gale AJ, Pellequer JL, Getzoff ED, Griffin JH. Structural basis for haemophilia A caused by mutations in the C domains of blood coagulation factor VIII. Thromb Haemost 2000; 83: 78-85.
6. Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5 Å resolution. Nature 1999; 402: 439-42.
7. Stoilova-McPhie S, Villoutreix B, Mertens K, Kemball-Cook G, Holzenburg A. 3-dimensional structure of membrane-bound coagulation factor VIII. Modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood 2002; 99: 1215-23.
8. Lazarchick J, Hoyer L. Immunoradiometric measurement of the factor VIII procoagulant antigen. J Clin Invest 1978; 62: 1048-52.
9. Reisner HM, Price WA, Blatt PM, Barrow ES, Graham JB. Factor VIII coagulant antigen in hemophilic plasma: a comparison of five alloantibodies. Blood 1980; 56: 615-9.
10. Girma JP, Lavergne JM, Meyer D, Larrieu MJ. Immunoradiometric assay of factor VIII. coagulant antigen using four human antibodies. Study of 27 cases of haemophilia A. Br J Haematol 1981; 47: 269-82.
11. Gitschier J, Wood WI, Shuman MA, Lawn RM. Identification of a missense mutation in the factor VIII gene of a mild haemophiliac. Science 1986; 232: 1415-6.
12. Higuchi M, Antonarakis SE, Kasch L, Oldenburg J, Economou-Petersen E, Olek K, Arai M, Inaba H, Kazazian HH Jr. Molecular characterization of mild-to-moderate hemophilia A. Detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis. Proc Natl Acad Sci USA 1991; 88: 8307-11.
13. Naylor JA, Green PM, Rizza CR, Giannelli F. Analysis of factor VIII mRNA reveals defects in everyone of 28 haemophilia A patients. Hum Mol Genet 1993; 2: 11-7.
14. Schwaab R, Oldenburg J, Schwaab U, Johnson DJ, Schmidt W, Olek K, Brackman HH, Tuddenham EG. Characterization of mutations within the factor VIII gene of 73 unrelated mild and moderate haemophiliacs. Br J Haematol 1995; 91: 458-64.
15. Kemball-Cook G. HAMSTeRS - The haemophilia A mutation database. http://europium.csc.mrc.ac.uk.
16. Voorberg J, de Laaf RT, Koster PM, Van Mourik JA. Intracellular retention of a factor VIII protein with an Arg2307→Gln mutation as a cause of haemophilia A. Biochem J 1996; 318: 931-7.
17. Pipe SW, Kaufman RJ. Factor VIII, C2 domain missense mutations exhibit defective trafficking of biological functional proteins. J Biol Chem 1996; 271: 25671-6.
18. Amano K, Sarkar R, Pemberton S, Kemball-Cook G, Kazazian H, Kaufman RJ. The molecular basis for cross-reacting material-positive haemophilia A due to missense mutations within the A2 domain of factor VIII. Blood 1998; 91: 538-48.
19. Roelse J, de Laaf R, Timmermans S, Peters M, van Mourik J, Voorberg J. Intracellular accumulation of factor VIII induced by missense mutations Arg593→Cys and Asn618→Ser explains cross-reacting material-reduced haemophilia A. Br J Haematol 2000; 108: 241-6.
20. Jacquemin M, Lavend'homme R, Benhida A, Vanzieleghem B, d'Oiron R, Lavergne JM, Brackmann HH, Schwaab R, VandenDriessche T, Chuah MK, Hoylaerts M, Gilles JG, Peerlinck K, Vermylen J, Saint-Remy JM. A novel cause of mild/moderate haemophilia A. mutations scattered in the factor VIII, C1 domain reduce factor VIII binding to von Willebrand factor. Blood 2000; 96: 958-65.
21. Jorieux S, Tuley EA, Gaucher C, Mazurier C, Sadler JE. The mutation Arg(53)→Trp causes von Willebrand disease Normandy by abolishing binding to factor VIII. Studies with recombinant vonWillebrand factor. Blood 1992; 79: 563.
22. Hamer RJ, Koedam JA, Beeser-Visser NH, Bertina RM, Van Mourik JA, Sixma JJ. Factor VIII binds to von Willebrand factor via its Mr 80,000 light chain. Eur J Biochem 1987; 166: 37-43.
23. Lollar P, Hill-Eubanks DC, Parker GC. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988; 263: 10451-5.
24. Leyte A, Verbeet MP, Brodniewicz-Proba T, Van Mourik JA, Mertens K. The interaction between human blood coagulation factor VIII and von Willebrand factor. Biochem J 1989; 257: 679-83.
25. Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, Terada S, Fukui H. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69: 240-6.
26. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269: 11601-5.
27. Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor. J Biol Chem 1997; 272: 18007-14.
28. Leyte A, van Schijndel HB, Niehrs C, Huttner WB, VerbeetMP, Mertens K, van Mourik JA. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 1991; 266: 740-6.
29. Pittman DD, Wang JH, Kaufman RJ. Identification and functional importance of tyrosine sulfate residues within recombinant factor VIII. Biochemistry 1992; 31: 3315-25.
30. Michnick DA, Pittman DB, Wise RJ, Kaufman RJ. Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage. J Biol Chem 1994; 269: 20095-102.
31. Jacquemin MG, d'Oiron R, Lavend'homme R, Lavergne JM, Brackmann HH, Schwaab R, Peerlinck K, Gilles JGG, Vermylen J, Saint-Remy JMR. Point mutations scattered in the FVIII C1 and C2 domains reduce FVIII binding to vWF and are associated to mild/moderate haemophilia A. Thromb Haemost (Suppl) 1999; 222a.
32. Jacquemin M, Benhida A, Peerlinck K, Desqueper B, Vander Elst L, Lavend'homme R, d'Oiron R, Schwaab R, Bakkus M, Thielemans K, Gilles JG, Vermylen J, Saint-Remy JM. A human antibody directed to the factor VIII, C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood 2000; 95: 156-63.
33. Gilles JG, Lavend'homme R, Peerlinck K, Jacquemin MG, Hoylaerts M, Jorieux S, Mazurier C, Vermylen J, Saint-Remy JM. Some FVIII inhibitors recognise a FVIII epitope(s) that is present only on FVIIIVWF complexes. Thromb Haemost 1999; 82: 40-5.
34. Gilbert G, Kaufmann RJ, Arena AA, Miao H, Pipe SW. Four hydrophobic amino acids of the factor VIII, C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs. J Biol Chem 2002; 277: 6374-81.
35. Koradi R, Billeter M, Wüthrich K. MolMol: a program for display and analysis of macromolecular structures. J Mol Graphics 1996; 14: 51-5.
36. Arai M, Inaba H, Higuchi M, Antonarakis SE, Kazazian HH Jr, Fujimaki M, Hoyer LW. Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372-histidine). Proc Natl Acad Sci USA 1989; 86: 4277-81.
37. Shima M, Ware J, Yoshioka A, Fukui H, Fulcher CA. An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule. Blood 1989; 74: 1612-7.
38. Arai M, Higuchi M, Antonarakis SE, Kazazian HH Jr, Phillips JA, 3rd Janco RL, Hoyer LW. Characterization of a thrombin cleavage site mutation (Arg 1689 to Cys) in the factor VIII gene of two unrelated patients with cross-reacting material-positive haemophilia A. Blood 1990; 75: 384-9.
39. Gitshier J, Kogan S, Levinson B, Tuddenham E. Mutations of factor VIII cleavage sites in haemophilia A. Blood 1988; 72: 1022-8.
40. O'Brien DP, Tuddenham EG. Purification and characterization of factor VIII 1,689-Cys: a nonfunctional cofactor occurring in a patient with severe haemophilia A. Blood 1989; 73: 2117-22.
41. Goodeve AC, Hinks JL, Nesbitt IM, Sampson B, Burgess C, Khair K, Leisner R, Kitchen S, Peake IR, Makris M. Unusual discrepant factor VIII. C assays in haemophilia A patients with Tyr346Cys and Glu321Lys FVIII gene mutations. Thromb Haemost (Suppl.) 2001 (Abstract P1370).
42. Mumford AD, Kemball-Cook G, O'Donnell J, Johnson DJ, Manning R, McVey JH, Tuddenham EGD, Laffan M. A novel Factor VIII variant Tyr346Cys in the acidic a1 domain is associated with an unusual onestage/two stage assay discrepancy and delayed thrombin activation. Thromb Haemost (Suppl) 2001 (Abstract P2861).
43. Rudzki Z, Duncan EM, Casey GJ, Neumann M, Favaloro EJ, Lloyd JV. Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br J Haematol 1996; 94: 400-6.
44. Mazurier C, Gaucher C, Jorieux S, Parquet-Gernez A. Mutations in the FVIII gene in seven families with mild haemophilia A. Br J Haematol 1997; 96: 426-7.
45. Keeling DM, Sukhu K, Kemball-Cook G, Waseem N, Bagnall R, Lloyd JV. Diagnostic importance of the two-stage factor VIII. C assay demonstrated by a case of mild haemophilia associated with His1954→Leu substitution in the factor VIII, A3 domain. Br J Haematol 1999; 105: 1123-6.
46. Schwaab R, Oldenburg J, Kemball-Cook G, Albert T, Juhler C, Hanfland P, Ingerslev J. Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family. Br J Haematol 2000; 109: 523-8.
47. Pipe SW, Eickhorst AN, McKinley SH, Saenko EL, Kaufman RJ. Mild haemophilia A caused by increased rate of factor VIII, A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood 1999; 93: 176-83.
48. Pipe SW, Saenko EL, Eickhorst AN, Kemball-Cook G, Kaufman RJ. Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood 2001; 97: 685-91.
49. Celie PH, Van Stempvoort G, Jorieux S, Mazurier C, Van Mourik JA, Mertens K. Substitution of Arg527 and Arg531 in factor VIII associated with mild haemophilia A. characterization in terms of subunit interaction and cofactor function. Br J Haematol 1999; 106: 792-800.
50. Fay P, Beattie T, Huggins C, Regan L. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem 1994; 269: 20522-7.
51. Jorquera J, McClintock RA, Roberts JL, MacDonald MJ, Houghton RA, Fulcher CA. Synthetic peptides derived from residues 698-710 of factor VIII inhibit FIXa activity. Circulation 1992; 96: 2725.
52. Lenting PJ, van de Loo JW, Donath MJ, van Mourik JA, Mertens K. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem 1996; 271: 1935-40.
53. Roelse JC, de Laaf RTM, Mertens K, van Mourik JA, Oldenburg J, Voorberg J. Altered sensitivity towards factor IXa explains assay discrepancies in plasma of haemophilia A patients with a Glu720->Lys substitution in factor VIII. Thromb Haemost (Suppl) 1999; 2 (Abstract 5).
54. Mazurier C, Van Mourik JA, Mertens K. Substitution of Arg527 and Arg531 in factor VIII associated with mild haemophilia A: characterization in terms of subunit interaction and cofactor function. Br J Haematol 1999; 106: 792-800.